Book a Demo
Andrew Dunn
Gray shield icon
Is this you?
Claim your profile.

Andrew Dunn

Senior Biopharma Correspondent

AS SEEN ON
Endpoints News, State Policy Network, The Charlotte Observer, The Herald-Sun (Durham, NC), Bloomberg News

Preston's Summary

Andrew Dunn is a senior biopharma correspondent at Endpoints News. He specializes in reporting on the intersection of biotechnology and pharmaceuticals, with a keen focus on AI's emerging role in the sector, cell and gene therapy, and the financial dynamics of medicine. His insights and analyses have been featured in prominent outlets such as Yahoo News UK, Business Insider, and Forbes.

Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston

Geo Focus

Charlotte, United States (Local)

Coverage Attributes:

Beta
Informative: 45 %
Opinion: 23 %
Data Driven: 8 %
Reviews: 7 %
Interviews Q&as: 5 %

Themes Covered:

Not enough data icon

Not enough data

Most Recent Topics:

  • Elections
  • Government
  • Politics
  • Public Policy
  • AI Platforms
  • Healthcare Administration
  • Housing Market
  • Real Estate Development

Pitching Insights

Andrew Dunn's coverage primarily focuses on the healthcare and pharmaceutical industry, particularly on biotech, pharmaceutical companies, and research & development. He also covers business and finance aspects related to these sectors.

Given his high percentage of press releases in his coverage attributes, Andrew might be more inclined towards news directly from companies within the healthcare and pharmaceutical industries. Therefore, he may be interested in pitches that provide exclusive insights into new drug developments, breakthrough technologies or significant funding announcements within these sectors.

As Andrew often writes about CEOs and investments in the industry, experts who can offer unique perspectives on leadership strategies within biotech/pharmaceutical companies or trends in R&D investment could grab his attention.

This information evolves through artificial intelligence and human feedback. Improve this profile .

Journalists With Similar Coverage:

Based on similarity of content.
Ayla Ellison

Ayla Ellison

Editor-In-Chief
******on@*********om
Publications
FierceHealth, Biotech, Fierce Pharma
Most recent topics
Not enough data
Elaine Chen

Elaine Chen

National Biotech Reporter
*********en@**********om
Publications
DIGITIMES Asia, STAT News, Tech News Tube
Most recent topics
Not enough data
Drew Armstrong

Drew Armstrong

Designer
***w@********om
Publications
Endpoints News
Most recent topics
Not enough data
Zoey Becker

Zoey Becker

Staff Writer, Fierce Pharma
******r@*********om
Publications
Fierce Pharma, Biotech
Most recent topics
Not enough data
Daniel Barnes

Daniel Barnes

Associate Producer
**********nes@********om
Publications
POLITICO, Hoodline, yahoo.com
Most recent topics
Not enough data
Steven Chung

Steven Chung

Publications
Above the Law, GeneOnline
Most recent topics
Not enough data

Articles

AI is rewriting the criteria for hiring product and engineering leadership

AI is rewriting the criteria for hiring product and engineering leadership

By: Sara Clark, Andrew Dunn

Eighteen months ago, some of the practices that define today's best AI-era leaders might have looked like red flags. Small teams with no structured roadmap. Leaders openly saying, “I don't know yet.” CTOs redesigning the entire org rather than managing it. Practices that were anti-patterns are becoming normalized and codified in a new executive hiring playbook.

© 2026 Intelligent Relations